ALS Association Launches Campaign Against Insurance Denials
The ALS Association has launched the 'We Are Undeniable' campaign to assist families in appealing insurance denials related to treatments, equipment, and care for people with amyotrophic lateral sclerosis (ALS). The initiative includes a free appeal letter builder called the Undeniable Kit. A review of policies from 19 commercial insurers revealed that nearly all imposed additional requirements not mandated by the FDA for Qalsody®, an approved gene-targeted ALS treatment. The campaign highlights cases like Kayla Gonzalez, who faced denial after her insurer labeled the drug 'investigational.' The Association helped overturn the decision but noted such delays are common. Surveys show about one-third of patients experience denials in medication or care claims, with appeals taking up to six months and often resulting in partial approvals. The ALS Association is pushing for systemic change by challenging insurers' coverage policies that add unnecessary barriers to FDA-approved treatments.
Topics: ALS FDA approval gene-targeted treatment insurance barriers patient advocacy